Urinary tract infections (UTIs) are among the most common causes of hospitalization in children, with a rising prevalence of extended-spectrum beta-lactamase-producing organisms (ESBL). The purpose of this study was to identify risk factors and treatment outcomes of children with ESBL-UTI. A retrospective case-control study of hospitalized children was performed from July 2014 till December 2017. Medical records from patients with a positive urine culture were reviewed and included in the study if they met criteria for UTI. Cases were defined as ESBL-UTI, while controls were defined as non-ESBL-UTI patients. This study confirmed that there are certain risk factors, such as previous UTI, recent antibiotic use, urinary tract abnormalities, recent hospital admission, and nonrenal comorbidities, that are associated with ESBL-UTI. Most of the patients with ESBL-UTI responded to discordant antibiotics. Other significant outcomes in patients with ESBL-UTI included a longer length of stay and longer intravenous antibiotic therapy.

尿路感染 (UTI) 是导致儿童住院的最常见原因之一，其中产超广谱 β-内酰胺酶微生物 (ESBL) 的患病率不断上升。本研究的目的是确定 ESBL-UTI 患儿的危险因素和治疗结果。2014 年 7 月至 2017 年 12 月对住院儿童进行了回顾性病例对照研究。审查了尿培养阳性患者的医疗记录，如果他们符合 UTI 标准，则将其纳入研究。病例被定义为 ESBL-UTI，而对照组被定义为非 ESBL-UTI 患者。这项研究证实，存在与 ESBL-UTI 相关的某些风险因素，例如既往 UTI、近期抗生素使用、尿路异常、近期住院和非肾脏合并症。大多数 ESBL-UTI 患者对不一致的抗生素有反应。ESBL-UTI 患者的其他重要结果包括更长的住院时间和更长的静脉内抗生素治疗。